| Abbreviation | Definition |
| ADC | antibody–drug conjugate |
| BCG | bacillus Calmette–Guérin |
| CGP | comprehensive genomic profiling |
| CI | confidence interval |
| CPS | combined positive score |
| DAB | diaminobenzidine |
| dd-MVAC | dose-dense methotrexate, vinblastine, doxorubicin and cisplatin |
| ECOG | Eastern Cooperative Oncology Group |
| EV | enfortumab vedotin |
| FDR | false discovery rate |
| FFPE | formalin-fixed paraffin-embedded |
| HR | hazard ratio |
| ICI | immune checkpoint inhibitor |
| IHC | immunohistochemistry |
| IQR | interquartile range |
| ITE | impossible to evaluate |
| la/mUC | locally advanced or metastatic urothelial carcinoma |
| MIBC | muscle-invasive bladder cancer |
| MSI | microsatellite instability |
| NAC | neoadjuvant chemotherapy |
| OS | overall survival |
| PBC | platinum-based chemotherapy |
| pCR | pathologic complete response |
| RFS | recurrence-free survival |
| RT | radiotherapy |
| TC | tumour cell (score) |
| TIL | tumour-infiltrating lymphocyte |
| TMB | tumour mutational burden |
| TSO-500 | TruSight Oncology 500 |
| TURBT | transurethral resection of bladder tumour |
| UC | urothelial carcinoma |
| UTUC | upper-tract urothelial carcinoma |
| VAF | variant allele frequency |
| VUS | variant of uncertain significance |
| WES | whole-exome sequencing |